Contact Us marketing@medicilon.com
logo icon
Stock Code
688202
|
中
|
中 Close icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
INNOVATION DRIVEN, QUALITY FOCUSED
MEDICILON
INNOVATION DRIVEN, QUALITY FOCUSED
Reliable CRO with integrated preclinical R&D
Learn more
PROFESSIONAL EXPERTISE POWERING R&D
MEDICILON
PROFESSIONAL EXPERTISE POWERING R&D
Strict quality inspections for superior drug development
Learn more
EFFICIENT MANAGEMENT DELIVERS WIN-WIN COLLABORATION
MEDICILON
EFFICIENT MANAGEMENT DELIVERS WIN-WIN COLLABORATION
Efficient processes that accelerate new drug R&D
Learn more
WE FORGE FORWARD, DRIVEN BY OUR UNYIELDING EFFORTS
MEDICILON
WE FORGE FORWARD, DRIVEN BY OUR UNYIELDING EFFORTS
Great career to head to new drug R&D
Learn more
prev page
next page
Official Promo Official Promo
Official promo
about medicilon
about medicilon

From drug discovery to IND filings

We aim to accelerate R&D through higher efficiency and lower costs

Medicilon is committed to providing integrated preclinical research for pharmaceutical enterprises, research institutions, and scientific researchers around the world, and promoting new drug research as a preclinical R&D outsourcing service provider.

Learn more
prev page next page
2024-11-19Medicilon Events
Medicilon Boston's Second R&D Center Grandly Sets Sail
On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets.
Learn more
2024-10-08Medicilon Events
Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.
Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
Learn more
2024-09-13Medicilon Events
Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company
Recently, Shanghai Medicilon Inc. (Medicilon) officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).
Learn more
2024-08-29Medicilon Events
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA.
Learn more
2024-07-31Medicilon Events
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
On July 17th, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.
Learn more
2024-07-26Medicilon Events
Recognition for Service! Medicilon Receives the "Excellent Service Award" from Allorion Therapeutics
On July 17, Dr. Yaoyu Chen, Co-founder of Allorion Therapeutics (Allorion), and Dr. Jiaqi Liang, Head of Biology, visited Medicilon's Chuansha campus in Shanghai to present the "Excellent Service Award" to Medicilon's pharmacology department.
Learn more
2024-07-22Medicilon Events
Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!
Recently, the Analytical Testing Center of Shanghai Medicilon Inc. (Medicilon) successfully passed the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
Learn more
2024-07-10Medicilon Events
Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development
Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo) in the fields of neurological disorders, ophthalmic diseases, and cardiovascular system drugs​.
Learn more
2024-06-20Medicilon Events
Medicilon AI Drug Discovery Service Platform: An Efficient Booster for New Drug Development
Medicilon's AI technology service platform can provide protein structure prediction and simulation, binding site discovery, information extraction and cleansing, as well as customized project database construction, meeting diverse needs of researchers.
Learn more
2024-06-13Medicilon Events
Medicilon Interview - Sungening Biological has successfully authorized collaboration, and Dr. Chenguang Yuan elaborated on the market trends and innovations in antifungal drugs
Sungening Biological (Sungening) has successfully obtained an implicit permission from the National Medical Products Administration for clinical trials (acceptance number: CXHL2400203) for its first innovative drug, SG1001.
Learn more
2024-11-19Medicilon Events
Medicilon Boston's Second R&D Center Grandly Sets Sail
On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets.
Learn more
2024-10-08Medicilon Events
Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.
Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
Learn more
2024-09-13Medicilon Events
Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company
Recently, Shanghai Medicilon Inc. (Medicilon) officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).
Learn more
2024-08-29Medicilon Events
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA.
Learn more
2024-07-31Medicilon Events
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
On July 17th, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.
Learn more
2024-07-26Medicilon Events
Recognition for Service! Medicilon Receives the "Excellent Service Award" from Allorion Therapeutics
On July 17, Dr. Yaoyu Chen, Co-founder of Allorion Therapeutics (Allorion), and Dr. Jiaqi Liang, Head of Biology, visited Medicilon's Chuansha campus in Shanghai to present the "Excellent Service Award" to Medicilon's pharmacology department.
Learn more
2024-07-22Medicilon Events
Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!
Recently, the Analytical Testing Center of Shanghai Medicilon Inc. (Medicilon) successfully passed the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
Learn more
2024-07-10Medicilon Events
Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development
Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo) in the fields of neurological disorders, ophthalmic diseases, and cardiovascular system drugs​.
Learn more
2024-06-20Medicilon Events
Medicilon AI Drug Discovery Service Platform: An Efficient Booster for New Drug Development
Medicilon's AI technology service platform can provide protein structure prediction and simulation, binding site discovery, information extraction and cleansing, as well as customized project database construction, meeting diverse needs of researchers.
Learn more
2024-06-13Medicilon Events
Medicilon Interview - Sungening Biological has successfully authorized collaboration, and Dr. Chenguang Yuan elaborated on the market trends and innovations in antifungal drugs
Sungening Biological (Sungening) has successfully obtained an implicit permission from the National Medical Products Administration for clinical trials (acceptance number: CXHL2400203) for its first innovative drug, SG1001.
Learn more
About Medicilon
About Medicilon
About Medicilon
About Medicilon
One-stop preclinical
pharmaceutical R&D outsourcing service
Discover breakthrough drugs with our scientific knowledge and expertise
Drug Discovery
Drug Discovery
Learn more
About Medicilon
One-stop preclinical
pharmaceutical R&D outsourcing service
We coordinate the entire new drug R&D process, comprehensively optimizing the cost, schedule and quality
Pharmaceutical Research
Pharmaceutical Research
Learn more
About Medicilon
One-stop preclinical
pharmaceutical R&D outsourcing service
With our global vision and dedication to excellence, we have gained particular insights into the clinical manifestation of drugs
Preclinical research
Preclinical research
Learn more
One-stop preclinical
pharmaceutical R&D outsourcing service
Discover breakthrough drugs with our scientific knowledge and expertise
Drug Discovery
Drug Discovery
Learn more
One-stop preclinical
pharmaceutical R&D outsourcing service
We coordinate the entire new drug R&D process, comprehensively optimizing the cost, schedule and quality
Pharmaceutical Research
Pharmaceutical Research
Learn more
One-stop preclinical
pharmaceutical R&D outsourcing service
With our global vision and dedication to excellence, we have gained particular insights into the clinical manifestation of drugs
Preclinical research
Preclinical research
Learn more
SOCIAL RESPONSIBILITY
Strive for the unfinished business of human health
Faster, better, and stronger, Medicilon is always on its way
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->